Drug intelligence / Profile preview

Lactiplantibacillus plantarum Lb41

Development stage: Preclinical
Lead developer: Konkuk University
Modality: Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
Administration: Oral

Overview

Lactiplantibacillus plantarum Lb41 is a specific strain of the lactic acid bacterium Lactiplantibacillus plantarum, isolated from kimchi and characterized for its probiotic properties. It demonstrates high viability under gastric and bile acid conditions, strong adhesion to intestinal epithelial cells, resistance to several antibiotics, and a lack of β-glucuronidase production. Lb41 exhibits antiproliferative effects on certain cancer cell lines and reduces nitric oxide production by macrophages, indicating potential immunomodulatory properties. This strain has been studied for use as a probiotic in foods, such as cottage cheese, where it maintains high levels of viable bacteria without altering physicochemical characteristics of the carrier food. Its main mechanism is the modulation of the gut microbiome and beneficial interaction with host immune and digestive processes[1].

Other names: Lactobacillus plantarum Lb41

Beyond the preview

Go deeper on Lactiplantibacillus plantarum Lb41.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Lactiplantibacillus plantarum Lb41.

Explore the full profile